Metabolic Surgery for Atrial Fibrillation Elimination

NCT07027969 on ClinicalTrials.gov · last registry update 2026-04-17

Registered but not yet open, with 100 participants planned. Due to report 31 December 2029, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Relative change in total duration of being in atrial fibrillation (AF). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for atrial fibrillation — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Ali Aminian
Sponsor type: Other
Enrollment: 100
Started: 2026-11-01
Primary completion: 2029-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Relative change in total duration of being in atrial fibrillation (AF)

Conditions studied

Atrial Fibrillation · Obesity and Obesity-related Medical Conditions

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.